Skip to content

T · 4578.T · DRUG MANUFACTURERS - GENERAL

Otsuka Holdings Co., Ltd. (4578.T) intrinsic value and stock valuation

$12,390.00as of 2026-11-21 · Mkt cap 5.89T

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Otsuka Holdings Co., Ltd. DCF and intrinsic value

InvestorsCraft values 4578.T with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from 4578.T’s statements →

Otsuka Holdings Co., Ltd. Graham Number

Graham Number: $9,493.88d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - General Tokyo 101-0048 otsuka.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$2.47T+11.7% 5y CAGRd
20112025
Net income
$363.2B+19.6% 5y CAGRd
20112025
Free cash flow
$315.7B+11.4% 5y CAGRd
20112025
Total equity
$3.1T+10.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$2.47T$2.33T$2.02T$1.74T$1.5T
Operating income$412.4B$396.9B$139.6B$150.3B$148.6B
Net income$363.2B$343.1B$121.6B$133.9B$125.5B
EPSd$685.1M$633.8M$224.1M$246.8M$231.3M
Operating cash flow$403.6B$354.6B$283.2B$211.8B$228.9B
Capital expenditure-$-87.84B-$-95.56B-$-90.74B-$-60.95B-$-52.45B
Free cash flow$315.7B$259.1B$192.5B$150.9B$176.4B
Total assets$4.2T$3.74T$3.36T$3.1T$2.82T
Total debt$228B$189.4B$214.2B$194.2B$212.5B
Net debt-$-306.67B-$-236.79B-$-299.15B-$-277.47B-$-198.23B
Total equity$3.1T$2.78T$2.44T$2.26T$2.05T
Cash and short-term investments$534.6B$426.2B$513.3B$471.6B$410.7B
Income statement
20252024202320222021
Revenue$2.47T$2.33T$2.02T$1.74T$1.5T
Cost of revenue$699.1B$660.4B$611.2B$569.5B$495B
Gross profit$1.77T$1.67T$1.41T$1.17T$1T
Research and development expenses$352.8B$314.2B$307.8B$275.2B$232.3B
Selling, general and administrative expenses$1T$958.3B$807.4B$724.1B$622.3B
Other expenses$0.00$1M$152.6B$18.8B$1M
Operating expenses$1.36T$1.27T$1.27T$1.02T$854.6B
Cost and expenses$2.06T$1.93T$1.88T$1.59T$1.35T
Interest income$15.7B$21.1B$9.57B$28.7B$14B
Interest expense$27B$8.79B$6.52B$6.06B$4.84B
Depreciation and amortization$116.2B$108B$93.7B$93.8B$84.9B
Ebitda$528.6B$523B$385.4B$279.8B$231.4B
Operating income$412.4B$396.9B$139.6B$150.3B$148.6B
Total other income/expenses, net$55.6B-$-61B$3.04B$22.6B$15B
Income before tax$468B$335.9B$142.7B$173B$163.6B
Income tax expense$101.8B-$-11.42B$17.2B$35.7B$34.4B
Net income$363.2B$343.1B$121.6B$133.9B$125.5B
Weighted average shares outstanding$530.1M$541.4M$542.7M$542.6M$542.4M
Weighted average diluted shares outstanding$530.1M$541.4M$542.7M$542.6M$542.4M
Balance sheet
20252024202320222021
Cash and short-term investments$534.6B$426.2B$513.3B$471.6B$410.7B
Net receivables$570.3B$518.8B$493.7B$426.4B$388.7B
Inventory$374.3B$298.3B$249.6B$223.5B$180.4B
Total current assets$1.62T$1.37T$1.33T$1.19T$1.05T
Property, plant and equipment, net$696.8B$628.5B$553.4B$510.7B$487.1B
Goodwill and intangible assets$1.08T$993.7B$870B$915.2B$818.4B
Long-term investments$582B$521.1B$476.4B$419.2B$401.7B
Total non-current assets$2.58T$2.37T$2.03T$1.91T$1.77T
Total assets$4.2T$3.74T$3.36T$3.1T$2.82T
Accounts payable$225.6B$126.4B$117.8B$104.1B$93.9B
Short-term debt$61.1B$28.5B$88.3B$44.2B$50B
Deferred revenue$11.3B$14B$14.3B$13.4B$12.5B
Total current liabilities$749.1B$632.7B$667.2B$539.2B$467.9B
Long-term debt$166.9B$160.9B$125.9B$150B$162.5B
Deferred revenue, non-current$26B$35.4B$44.9B$50.7B$57.8B
Total non-current liabilities$348.7B$328.4B$257.7B$301.1B$307.8B
Capital lease obligations$79.1B$73.6B$56.7B$56.2B$59.7B
Total liabilities$1.1T$961.1B$924.9B$840.3B$775.7B
Common stock$81.7B$81.7B$81.7B$81.7B$81.7B
Retained earnings$2.21T$1.9T$1.62T$1.55T$1.48T
Accumulated other comprehensive income (loss)$403.2B$336.4B$229.2B$128.8B-$-14.05B
Total equity$3.1T$2.78T$2.44T$2.26T$2.05T
Total investments$582B$521.1B$476.4B$419.2B$401.7B
Total debt$228B$189.4B$214.2B$194.2B$212.5B
Net debt-$-306.67B-$-236.79B-$-299.15B-$-277.47B-$-198.23B
Cash flow statement
20252024202320222021
Net income$363.2B$343.1B$121.6B$133.9B$125.5B
Depreciation and amortization$116.2B$108B$97.8B$93.8B$84.9B
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital-$-124.91B-$-77.11B-$-38.12B-$-42.01B$37.1B
Accounts receivable-$-42.47B-$-9.51B-$-31.8B-$-22.48B$13.3B
Inventory-$-53.47B-$-38.58B-$-16.56B-$-21.7B$6.51B
Accounts payable-$-4.08B-$-14.64B-$-13.01B$1.39B-$-12.16B
Net cash provided by operating activities$403.6B$354.6B$283.2B$211.8B$228.9B
Investments in property, plant and equipment-$-141.67B-$-129.36B-$-114.67B-$-107.79B-$-113.15B
Acquisitions, net-$-87.66B-$-117.34B-$-70.59B$12B-$-6.34B
Net cash used for investing activities-$-162.56B-$-268.27B-$-190.63B-$-81.58B-$-95.29B
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-70.1B-$-50.02B-$-1M$0.00-$-1M
Dividends paid-$-70.98B-$-66.76B-$-55.65B-$-55.56B-$-55.98B
Net cash used for financing activities-$-136.37B-$-186.89B-$-60.17B-$-95.47B-$-95.84B
Net change in cash$108.5B-$-87.17B$41.7B$61B$53.8B
Cash at end of period$534.6B$426.2B$513.3B$471.6B$410.7B
Operating cash flow$403.6B$354.6B$283.2B$211.8B$228.9B
Capital expenditure-$-87.84B-$-95.56B-$-90.74B-$-60.95B-$-52.45B
Free cash flow$315.7B$259.1B$192.5B$150.9B$176.4B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Otsuka Holdings Co., Ltd.

        Otsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of oncology, cardiovascular system, renal system, digestive system, ophthalmology, diagnostics, and intravenous solutions, as well as medical devices businesses. It also provides EQUELLE, a product for women's health and beauty; BODYMAINTÉ Jelly, a conditioning food product; BODYMAINTÉ Drink, a drinkable-liquid; POCARI SWEAT, a drink; Calorie Mate, a nutritional food; OS-1, an oral rehydration solution; HINEX-R, a concentrated liquid diet; and Oronine H Ointment, a household antiseptic medicine. In addition, the company offers soft drinks, food products, and wines; chemicals; clinical testing and medical equipment; cosmetics; warehousing and transport services; analysis and measurement equipment; pharmaceutical intermediates; vehicle headlight testers; synthetic resin molded products; paper products; artificial turf; ceramic boards, ceramic walls, reliefs, terracotta, OT ceramics, and ceramic portraits and sign boards; functional films; stable isotopes; software and services to enhance management of mental healthcare systems; potassium titanate; polyolefin foams; spring and mineral water; industrial chemicals; hydrazine; insecticide and toiletry products; and adhesive tapes. Further, it operates a hotel. Otsuka Holdings Co., Ltd. was founded in 1921 and is based in Tokyo, Japan.

        CEO
        Makoto Inoue
        Employees
        35.34K
        Beta
        -0.05

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Otsuka Holdings Co., Ltd. (4578.T)?

        InvestorsCraft does not currently publish an intrinsic value for 4578.T. How the IC value is calculated.

        Is 4578.T undervalued?

        InvestorsCraft does not publish an undervaluation signal for 4578.T at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.